The University of Queensland, National Research Centre for Environmental Toxicology (Entox), Brisbane, Qld 4108, Australia.
Environ Sci Technol. 2011 May 1;45(9):3835-47. doi: 10.1021/es1030799. Epub 2011 Apr 7.
When micropollutants degrade in the environment, they may form persistent and toxic transformation products, which should be accounted for in the environmental risk assessment of the parent compounds. Transformation products have become a topic of interest not only with regard to their formation in the environment, but also during advanced water treatment processes, where disinfection byproducts can form from benign precursors. In addition, environmental risk assessment of human and veterinary pharmaceuticals requires inclusion of human metabolites as most pharmaceuticals are not excreted into wastewater in their original form, but are extensively metabolized. All three areas have developed their independent approaches to assess the risk associated with transformation product formation including hazard identification, exposure assessment, hazard assessment including dose-response characterization, and risk characterization. This review provides an overview and defines a link among those areas, emphasizing commonalities and encouraging a common approach. We distinguish among approaches to assess transformation products of individual pollutants that are undergoing a particular transformation process, e.g., biotransformation or (photo)oxidation, and approaches with the goal of prioritizing transformation products in terms of their contribution to environmental risk. We classify existing approaches for transformation product assessment in degradation studies as exposure- or effect-driven. In the exposure-driven approach, transformation products are identified and quantified by chemical analysis followed by effect assessment. In the effect-driven approach, a reaction mixture undergoes toxicity testing. If the decrease in toxicity parallels the decrease of parent compound concentration, the transformation products are considered to be irrelevant, and only when toxicity increases or the decrease is not proportional to the parent compound concentration are the TPs identified. For prioritization of transformation products in terms of their contribution to overall environmental risk, we integrate existing research into a coherent model-based, risk-driven framework. In the proposed framework, read-across from data of the parent compound to the transformation products is emphasized, but limitations to this approach are also discussed. Most prominently, we demonstrate how effect data for parent compounds can be used in combination with analysis of toxicophore structures and bioconcentration potential to facilitate transformation product effect assessment.
当环境中的微量污染物降解时,它们可能会形成持久性和有毒的转化产物,这些产物应在母体化合物的环境风险评估中加以考虑。转化产物不仅在其在环境中的形成过程中,而且在先进的水处理过程中,从良性前体形成消毒副产物时,都成为了一个关注的话题。此外,人类和兽医药品的环境风险评估需要包括人体代谢物,因为大多数药品不会以其原始形式排泄到废水中,而是被广泛代谢。这三个领域都已经开发出了独立的方法来评估与转化产物形成相关的风险,包括危害识别、暴露评估、危害评估包括剂量-反应特征描述和风险特征描述。本综述提供了一个概述,并定义了这些领域之间的联系,强调了共性并鼓励采用共同的方法。我们区分了正在经历特定转化过程(例如生物转化或(光)氧化)的个别污染物的转化产物的评估方法,以及旨在根据其对环境风险的贡献对转化产物进行优先排序的方法。我们将降解研究中转化产物评估的现有方法分为暴露驱动或效应驱动。在暴露驱动的方法中,通过化学分析识别和量化转化产物,然后进行效应评估。在效应驱动的方法中,反应混合物进行毒性测试。如果毒性的降低与母体化合物浓度的降低平行,则认为转化产物不相关,只有当毒性增加或降低与母体化合物浓度不成比例时,才确定 TPs。为了根据其对总体环境风险的贡献对转化产物进行优先级排序,我们将现有的研究纳入一个连贯的基于模型的风险驱动框架中。在所提出的框架中,强调了从母体化合物到转化产物的读取相关性,但也讨论了这种方法的局限性。最突出的是,我们展示了如何将母体化合物的数据与毒性基团结构和生物浓缩潜力的分析结合起来,以促进转化产物的效应评估。